Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...

Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...

CHICAGO, March 5, 2026 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone ...

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations. In this Q&A, Avitzur breaks down the ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is now approved for treating adults with progressive pulmonary fibrosis (PPF) that causes gradual and permanent scarring in the lungs, ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...

EL PASO COUNTY, Colo. (KRDO) -- The Lewis Palmer School District 38 announced it will be closed on Dec. 16 after receiving information from law enforcement of a potential threat involving schools in ...

Idiopathic pulmonary fibrosis (IPF) is a chronic disease in which healthy lung tissue is gradually replaced by scar tissue. While the early events that initiate this change are poorly understood, ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...